Literature DB >> 14624797

Role for standards in assays of botulinum toxins: international collaborative study of three preparations of botulinum type A toxin.

Dorothea Sesardic1, Tong Leung, Rose Gaines Das.   

Abstract

The biological activity of therapeutic preparations of botulinum type A toxin is currently expressed in units defined on the basis of the median lethal intraperitoneal dose of that preparation in mice at 72 h, the LD50 dose. In this study we describe the comparison, by ten laboratories in five countries, of three different formulations of botulinum type A toxin using the mouse lethality test, and also using the relative activities of the preparations. The results of this study show that use of a standard preparation and expression of relative potency gives substantially greater consistency between and within laboratories than when mouse LD50 unit is used to define activity of botulinum toxin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624797     DOI: 10.1016/j.biologicals.2003.08.001

Source DB:  PubMed          Journal:  Biologicals        ISSN: 1045-1056            Impact factor:   1.856


  21 in total

1.  Biological activity of two botulinum toxin type A complexes (Dysport and Botox) in volunteers: a double-blind, randomized, dose-ranging study.

Authors:  K Wohlfarth; I Schwandt; F Wegner; T Jürgens; G Gelbrich; A Wagner; U Bogdahn; W Schulte-Mattler
Journal:  J Neurol       Date:  2008-10-07       Impact factor: 4.849

2.  The case for developing consensus standards for research in microbial pathogenesis: Bacillus anthracis toxins as an example.

Authors:  Molly A Hughes; Drusilla L Burns; Stephen J Juris; Wei-Jen Tang; Kristin H Clement; Linda J Eaton; Cassandra D Kelly-Cirino; Marian L McKee; Bradford S Powell; Brian L Bishop; Thomas L Rudge; Nancy Shine; Anita Verma; Melissa Swope Willis; Stephen A Morse
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

3.  In vitro detection and quantification of botulinum neurotoxin type e activity in avian blood.

Authors:  Timothy M Piazza; David S Blehert; F Mark Dunning; Brenda M Berlowski-Zier; Füsûn N Zeytin; Michael D Samuel; Ward C Tucker
Journal:  Appl Environ Microbiol       Date:  2011-09-09       Impact factor: 4.792

4.  A Novel Botulinum Neurotoxin, Previously Reported as Serotype H, Has a Hybrid-Like Structure With Regions of Similarity to the Structures of Serotypes A and F and Is Neutralized With Serotype A Antitoxin.

Authors:  Susan E Maslanka; Carolina Lúquez; Janet K Dykes; William H Tepp; Christina L Pier; Sabine Pellett; Brian H Raphael; Suzanne R Kalb; John R Barr; Agam Rao; Eric A Johnson
Journal:  J Infect Dis       Date:  2015-06-10       Impact factor: 5.226

5.  Detection of botulinum neurotoxin serotype A, B, and F proteolytic activity in complex matrices with picomolar to femtomolar sensitivity.

Authors:  F Mark Dunning; Daniel R Ruge; Timothy M Piazza; Larry H Stanker; Füsûn N Zeytin; Ward C Tucker
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

Review 6.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

7.  Is it possible to accurately determine content of botulinum neurotoxin type A in drug products?

Authors:  Dorothea Sesardic
Journal:  Drugs R D       Date:  2010

8.  Alternatives to animal testing: current status and future perspectives.

Authors:  Manfred Liebsch; Barbara Grune; Andrea Seiler; Daniel Butzke; Michael Oelgeschläger; Ralph Pirow; Sarah Adler; Christian Riebeling; Andreas Luch
Journal:  Arch Toxicol       Date:  2011-08       Impact factor: 5.153

9.  Pharmaceutical, biological, and clinical properties of botulinum neurotoxin type A products.

Authors:  Jürgen Frevert
Journal:  Drugs R D       Date:  2015-03

10.  Qualitative and Quantitative Detection of Botulinum Neurotoxins from Complex Matrices: Results of the First International Proficiency Test.

Authors:  Sylvia Worbs; Uwe Fiebig; Reinhard Zeleny; Heinz Schimmel; Andreas Rummel; Werner Luginbühl; Brigitte G Dorner
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.